Florence Nameere-Kivunike

Dr. Florence Nameere-Kivunike

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in The Electronic Journal of Information Systems in Developing Countries
Verified
Journal Article
Open access
PDF file
FNFlorence Nameere-Kivunike
Florence Nameere-Kivunike
LELove Ekenberg
Love Ekenberg
MDMats Danielson
Mats Danielson
FTF. F. Tusubira
F. F. Tusubira
Using a case from the healthcare delivery sector, we demonstrate how a structured evaluation approach can facilitate the measurement of actual ICT contributions in various contexts. Typically, such are intricate due to the complexities inherent in the environments, making it difficult to evaluate the relationship between ICT and the benefits it intends to achieve to a reasonable degree. The approach suggested in this paper tries to partly remedy some of these complications, by facilitating qualitative data elicitations, aggregation, analysis and evaluation. To make this computationally meaningful, a decision support tool for handling numerically imprecise information is used for the data analysis and evaluation details. The results of this indicate that such an approach makes at least some meaningful input for practitioners and policymakers. In comparison to the qualitative in-depth approaches this approach facilitates a one-point in time assessment, which is less resource intensive, but provides prompt and substantial insight on the development performance of ICT4D initiatives. A similar approach would also be applicable to different sectors, and can utilize a broader scope of criteria, as well as incorporate views from several categories of stakeholders.

2 November 2022 in The Electronic Journal of Information Systems in Developing Countries
Verified
Journal Article
Closed access
FNFlorence Nameere-Kivunike
Florence Nameere-Kivunike
EGElly A. Gamukama
Elly A. Gamukama
JNJoyce Nakatumba-Nabende
Joyce Nakatumba-Nabende
DMDaniel Mutembesa
Daniel Mutembesa
JTJeremy Francis Tusubira
Jeremy Francis Tusubira
GNGloria Namanya
Gloria Namanya

16 March 2026 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
MNMaria Magdalene Namaganda
Maria Magdalene Namaganda
SGStathis Gennatas
Stathis Gennatas
LMLaura Merson
Laura Merson
EGEsteban Garcia-Gallo
Esteban Garcia-Gallo
TETom Edinburgh
Tom Edinburgh
Gerald MboowaGerald Mboowa
Gerald Mboowa
The scale-up of antiretroviral therapy (ART) has transformed the HIV epidemic in sub-Saharan Africa, yet longitudinal public health insights from national programmatic cohorts remain scarce. As global targets move toward epidemic control and elimination of virological failure, understanding how profiles and outcomes of people living with HIV (PLWH) evolve in real-world settings is essential. The AIDS Support Organisation (TASO), Uganda’s largest HIV care provider, maintains one of the longest-running national registries of PLWH. We aimed to generate insights to inform targeted interventions, optimize programmatic responses and improve long-term care for PLWH in resource-constrained settings. We conducted a secondary analysis of routinely collected data within an open cohort of 54,348 PLWH enrolled at 11 TASO clinics between 2014–2024. Descriptive statistics summarized demographic, clinical, immunological, behavioral and socioeconomic characteristics at baseline and follow-up. At most recent recorded follow-up, 60.4% of PLWH were female with median age of 39 years (IQR 31–47); 55% aged 25–44 years. At ART initiation, non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens dominated (>90% through 2017), by 2024, > 99% of ART initiations were dolutegravir (DTG)- based, aligning with national policy. Immune recovery improved over study period; however, 12% still presented with CD4 < 200 cells/µL. Most PLWH initiated care in WHO stage I–II, and prevalence of advanced disease declined further at last record. Self-reported adherence exceeded 95%. Tuberculosis was the most frequent infectious comorbidity (5% prior history), whereas hypertension (3.9%) and diabetes (2.5%) were the leading non-communicable conditions. Socioeconomic vulnerability reported 57% with irregular income and 21% unemployed. Psychosocial stressors, including poverty and stigma, were common. Findings show progress alongside persistent gaps and structural barriers. They mandate earlier diagnosis, integrated tuberculosis and non-communicable disease management, strengthened socioeconomic support, and risk-stratified care using predictive modeling to reduce virological failure and drive Uganda toward 95–95–95 targets in resource-constrained settings.

6 October 2025 in The Electronic Journal of Information Systems in Developing Countries
Verified
Journal Article
Closed access
HNHawa Nyende
Hawa Nyende
AMAlice Mugisha
Alice Mugisha
MKMichael Kizito
Michael Kizito
FNFlorence Nameere-Kivunike
Florence Nameere-Kivunike

17 August 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RKRogers Kamulegeya
Rogers Kamulegeya
RNRose Nabatanzi
Rose Nabatanzi
DSDerrick Semugenze
Derrick Semugenze
FMFaridah Mugala
Faridah Mugala
MTMercy Takuwa
Mercy Takuwa
DKDavid Patrick Kateete
David Patrick Kateete
Background: Tuberculosis (TB) remains a leading cause of infectious disease mortality worldwide, and treatment failure contributes to ongoing transmission, drug resistance, and poor clinical outcomes. Artificial intelligence (AI) and machine learning (ML) approaches have attracted growing interest in predicting TB treatment outcomes, but the literature is heterogeneous and lacks a comprehensive synthesis. Methods: We systematically searched PubMed/MEDLINE and Embase (January 2000–October 2025) for studies developing or validating AI/ML models to predict TB treatment failure. Two reviewers independently screened records and extracted data on study characteristics, predictor modalities, algorithms, validation strategies, and performance metrics, i.e., area under the curve (AUC), sensitivity, specificity, and confidence intervals. Studies reporting AUC with confidence intervals or sufficient data for calculation were included in random-effects meta-analysis. Missing standard errors were estimated from sample sizes and event rates using established methods. Risk of bias was assessed using PROBAST. Subgroup analyses and meta-regression explored heterogeneity, and publication bias was assessed using funnel plots, Egger’s test, and trim-and-fill analysis. The study is registered with PROSPERO (CRD420251101443). Results: Thirty-four studies met the inclusion criteria. Publications increased markedly from 2019 onwards (91% of studies). Tree-based methods predominated (52.9%), and multimodal models (≥3 data types) were used in 41.2% of the studies. Nineteen studies (100,790 participants) contributed to the meta-analysis. The pooled AUC was 0.836 (95% CI 0.799–0.868), with substantial heterogeneity (I² = 97.9%). In subgroup analyses, studies including HIV-positive participants showed lower discrimination (AUC 0.748) than those excluding them (0.924). Only eight studies (23.5%) performed external validation, and only one study (2.9%) was rated low risk of bias overall (PROBAST), primarily due to analytical domain deficiencies. Egger’s test suggested publication bias (p = 0.024). Major evidence gaps included underrepresentation of high-burden countries, HIV-affected populations, social determinants, pediatric TB, and extrapulmonary disease. Conclusions: AI/ML models for predicting TB treatment failure show promising discrimination but are not yet ready for routine clinical implementation. Performance varies substantially across populations and settings, and methodological limitations, including inadequate validation, poor calibration assessment, and high risk of bias, limit confidence in current estimates. Future research should prioritize rigorous external validation, calibration assessment, and development in underrepresented populations, particularly HIV-affected and high TB burden settings.

4 June 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ENEmmanuel Nasinghe
Emmanuel Nasinghe
DMDenis Musinguzi
Denis Musinguzi
MTMercy Takuwa
Mercy Takuwa
RKRogers Kamulegeya
Rogers Kamulegeya
RNRose Nabatanzi
Rose Nabatanzi
DKDavid Patrick Kateete
David Patrick Kateete
Tuberculosis (TB) is prevalent in Uganda and overlaps with a high rate of HIV/TB coinfection. While nearly all hospital-based TB cases in Kampala, the capital of Uganda, show clear TB symptoms, 30% or more of undiagnosed TB cases found through active screening are asymptomatic. Additionally, the host risk factors for TB in Kampala cannot be distinguished from environmental risk factors. These TB-specific challenges are just part of the complexity, especially in areas with high HIV/AIDS burden. Data science techniques, especially Artificial Intelligence (AI) and Machine Learning (ML) algorithms, could help untangle this complexity by identifying factors related to the host, pathogen, and environment, which are difficult to explain or predict with traditional/conventional methods. In this project, we will use health data science approaches (AI/ML) to identify factors driving TB transmission within households and reasons for anti-TB treatment failure. We will utilize the computational resources at Makerere University and available demographic, clinical, and laboratory data from TB patients and their contacts to develop AI and ML algorithms. These will aim to: (1) identify patients at baseline (month 0) unlikely to convert their sputum or culture results by months 2 and 5, thus at risk of failing TB treatment; (2) identify household contacts of TB cases who are at risk of developing TB disease, as well as contacts who may resist TB infection despite repeated exposure to M. tuberculosis . Achieving these objectives will provide evidence that data science methods are effective for early detection of potential TB cases and high-risk patients, thereby helping to reduce TB transmission in the community. The study protocol received approval from the School of Biomedical Sciences IRB, protocol number SBS-2023-495.